Stockscreener 앱 받기
2.01
11.67%
0.21
시간 외 거래:
2.00
-0.010
-0.50%
전일 마감가:
$1.80
열려 있는:
$1.89
하루 거래량:
816.98K
Relative Volume:
2.09
시가총액:
$284.23M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-5.19%
1개월 성능:
-13.36%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$1.86
$2.28
1주일 범위
$1.78
$2.30
52주 변동 폭
$1.70
$26.01
Veraxa Biotech Ag Stock (VRXA) Company Profile
Compare VRXA vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRXA
Veraxa Biotech Ag
|
2.01 | 254.53M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Veraxa Biotech Ag 주식(VRXA)의 최신 뉴스
Veraxa Biotech (VRXA) moves bispecific ADC VXA-222 program forward - Stock Titan
VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - NewMediaWire
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - Benzinga
Veraxa Advances Bispecific ADC Candidate VXA-222 Following OmniAb Discovery Milestone - BioPharm International
VERAXA Biotech Advances Bispecific ADC Program VXA-222 Under OmniAb Collaboration - citybuzz -
VERAXA Biotech Shareholders Overwhelmingly Approve Corporate Governance and Financing Measures - citybuzz -
Veraxa Biotech AG Ord Shs (VRXA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Veraxa Biotech advances bispecific ADC from Omniab collaboration - BioWorld News
VERAXA Biotech Announces Advancement of VXA-222 Bispecific ADC Program in Collaboration with OmniAb - Quiver Quantitative
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb - NTB Kommunikasjon
Veraxa Biotech AG Ord Shs (VRXA) Balance Sheet - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
VRXA|Veraxa Biotech AG Ord Shs|Price:1.800|Chg%:-0.060 - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Veraxa Biotech shareholders approve governance changes By Investing.com - Investing.com India
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer - USA Today
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth - The Manila Times
VERAXA Biotech AG (VRXA) Appoints Christoph Erkel as Chief Scientific Officer - NewMediaWire
Veraxa Biotech AG Revenue Breakdown – FWB:J8L0 - TradingView
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer, Bolstering Solid Tumor Pipeline - citybuzz -
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel As Chief Scientific Officer - Menafn
VERAXA Biotech (VRXA) Advances BiTAC(R)-TCE Development With Positive Regulatory Feedback From Germany - Yahoo Finance
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Lead BiTAC Platform Development - citybuzz -
Veraxa Biotech names Christoph Erkel as chief scientific officer By Investing.com - Investing.com UK
VERAXA Biotech AG Appoints Christoph Erkel, Ph.D., as Chief Scientific Officer - Quiver Quantitative
VERAXA Taps 20-Year Antibody Expert to Guide New Cancer Treatments - Stock Titan
VERAXA Biotech Receives Positive Regulatory Guidance for BiTAC-TCE Platform from German Authority - citybuzz -
VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program - USA Today
symbol__ Stock Quote Price and Forecast - CNN
VERAXA Biotech Receives Regulatory Clarity on BiTAC-TCE Cancer Therapy Platform - citybuzz -
Veraxa Biotech AG Announces Regulatory Progress with Its BiTAC -TCE Development Plan - marketscreener.com
VERAXA Biotech (VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform - NewMediaWire
VERAXA Biotech (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform - TradingView
VERAXA Biotech Receives Positive Scientific Advice from Germany's PEI for its BiTAC®-TCE Program - citybiz
Veraxa Biotech receives feedback on BiTAC-TCE program - BioWorld News
VERAXA Biotech AG Receives Scientific Advice from Germany’s PEI on BiTAC-TCE Development Program - Quiver Quantitative
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan - The Manila Times
VERAXA cancer candidate targets two markers while sparing others - Stock Titan
Veraxa Biotech receives PEI scientific advice on BiTAC-TCE development plan - Bitget
VERAXA Biotech (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention - USA Today
Why VERAXA Biotech (VRXA) Could Benefit More Than Others From AI's Growing Impact on Drug R&D - Yahoo Finance
Why VERAXA Biotech (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D - Benzinga
VERAXA Biotech Leverages AI Partnership to Advance Cancer Therapy Platform - citybuzz -
VERAXA Biotech Appoints Carl von Halem as Interim CFO Amid Permanent Candidate Search - citybuzz -
VERAXA Biotech (VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development - NewMediaWire
VERAXA Biotech Partners with Ardigen to Integrate AI in Cancer Drug Development - citybuzz -
VERAXA Biotech (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development - Benzinga
Veraxa partners with Ardigen on AI-driven cancer target selection - Investing.com UK
Veraxa Biotech Ag (VRXA) 재무 분석
Veraxa Biotech Ag (VRXA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):